Nautilus Biotechnology (NASDAQ:NAUT) and Pressure BioSciences (OTCMKTS:PBIO) Critical Review

Pressure BioSciences (OTCMKTS:PBIOGet Rating) and Nautilus Biotechnology (NASDAQ:NAUTGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Institutional and Insider Ownership

0.1% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 47.9% of Nautilus Biotechnology shares are owned by institutional investors. 14.6% of Pressure BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pressure BioSciences and Nautilus Biotechnology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pressure BioSciences -1,006.69% N/A -735.75%
Nautilus Biotechnology N/A -15.29% -14.70%

Earnings & Valuation

This table compares Pressure BioSciences and Nautilus Biotechnology’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pressure BioSciences $2.00 million 7.37 -$20.15 million ($3.57) -0.47
Nautilus Biotechnology N/A N/A -$50.31 million ($0.57) -7.39

Pressure BioSciences has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Pressure BioSciences and Nautilus Biotechnology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pressure BioSciences 0 0 0 0 N/A
Nautilus Biotechnology 0 2 2 0 2.50

Nautilus Biotechnology has a consensus target price of $8.67, indicating a potential upside of 105.86%. Given Nautilus Biotechnology’s higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Pressure BioSciences.

Summary

Nautilus Biotechnology beats Pressure BioSciences on 6 of the 11 factors compared between the two stocks.

About Pressure BioSciences (Get Rating)

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Pressure BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.